NetworkNewsBreaks – VistaGen Therapeutics Inc. (
Post# of 130
(Total Views: 255)
Posted On: 03/22/2021 6:02:13 PM
NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. The objective is for PH94B to displace these and other benzodiazepines, which are widely used but addictive, as a viable treatment for social anxiety disorder (“SAD”) and other anxiety disorders and phobias. SAD is the third most common mental health disorder among Americans, and recent studies indicate that an estimated 20 million individuals suffer with the debilitating disorder. “Given the FDA’s recent Drug Safety Communication that outlined and highlighted the safety risks associated with benzodiazepine use, the implications resulting from this study are significant,” said VistaGen chief medical officer Mark Smith, M.D., Ph.D., in the press release. “PH94B may have the potential to displace benzodiazepines altogether and become the safer alternative to help the millions of Americans suffering from anxiety with limited options for safe, effective treatment options. These existing treatments can actually hurt instead of help. We look forward to launching our Phase 3 clinical development program for PH94B next quarter and continuing to push forward in our mission to get it into the hands of those in need as soon as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. The objective is for PH94B to displace these and other benzodiazepines, which are widely used but addictive, as a viable treatment for social anxiety disorder (“SAD”) and other anxiety disorders and phobias. SAD is the third most common mental health disorder among Americans, and recent studies indicate that an estimated 20 million individuals suffer with the debilitating disorder. “Given the FDA’s recent Drug Safety Communication that outlined and highlighted the safety risks associated with benzodiazepine use, the implications resulting from this study are significant,” said VistaGen chief medical officer Mark Smith, M.D., Ph.D., in the press release. “PH94B may have the potential to displace benzodiazepines altogether and become the safer alternative to help the millions of Americans suffering from anxiety with limited options for safe, effective treatment options. These existing treatments can actually hurt instead of help. We look forward to launching our Phase 3 clinical development program for PH94B next quarter and continuing to push forward in our mission to get it into the hands of those in need as soon as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)